Ann Oncol: The efficacy of Olapali monotherapy in patients with primary treatment for triple negative breast cancer

The anti-tumor effect of PARP inhibitors (PARPi) on breast cancer patients with BRCA1/2 (gBRCA1/2) mutations in the embryo line was determined.
although PARPi monotherapy is ineffective in patients with BRCA1/2 wild metastasis triple negative breast cancer (TNBC), the researchers speculate that PARPi may be effective for primary TNBC that has not been exposed to chemotherapy.
phase II PETREMAC trial, patients with primary TNBC-2 cm were treated with Olapali for up to 10 weeks before chemotherapy.
targeted DNA sequencing (360 genes) and BRCA1 methylation were collected from tumor biopsy tissue before and after Olapali's treatment.
, pre-treatment samples were analyzed for BRCAness (multiple connections dependent on probe amplification), PAM50 gene expression, RAD51 bits, tumor-soaked lymphocytes (TIL), and PD-L1.
60 mm (25 to 112 mm) of tumor diameter before treatment with a 1ogen recombinant gene mutation carried by the subjects.
18 (56.3%) of the 32 patients had an objective response (OR) to Olapali.
10 of the 18 respondents detected soymic cell or embryonic mutations affecting hr, 95% CI 33.7-75.4, while only 1 in 14 non-respondents (OR 7.1%; 1.3-31.5, P -0.008).
in tumors that did not carry HR mutations, 6/8 respondents and 3/13 non-responders showed BRCA1 high methylation (P-0.03).
, 16/18 respondents (88.9%) and 4/14 non-respondents (28.6%, P-0.0008) carried HR mutations and/or BRCA1 methylation.
excluded 1 gPALB2 and 4 gBRCA1/2 mutant carriers, 12/14 respondents (85.7%) and 3/13 non-respondents (23.1%, P-0.002) carry body cell HR mutations and/or BRCA1 methylation.
, low RAD51 score, high TIL, or high PD-L1 expression were all associated with Olapali efficacy, unlike BRCAness signatures or subsypes.
, first-time TNBC patients with HR deficiencies had a higher clinical response rate using Olapali therapy.